Sector News

Teva restructuring puts R&D programs on the chopping block

December 15, 2017
Life sciences

Teva Pharmaceutical has unveiled its restructuring plan—and it doesn’t look good for R&D.

The plan will address a number of key areas, including the closure or divestment of R&D sites, as well as an evaluation of the company’s R&D programs, CEO Kåre Schultz said in a letter to employees.

It is expected to affect a “significant number” of R&D facilities and other sites, Schultz said. Teva will also conduct a “thorough review of all R&D programs across the entire company,” with an eye on prioritizing core projects and dumping others, while somehow “maintaining a substantial pipeline.”

All told, the plan will lead to 14,000 layoffs, about 25% of Teva’s total workforce. Slated to start in 2018, the company will begin notifying affected employees over the next three months. Schultz did not detail the distribution of the job cuts, saying that “all businesses and regions will be affected.”

Israeli Prime Minister Benjamin Netanyahu has asked Schultz to limit the layoffs in Israel to a minimum, Reuters reported.

With the restructuring, Teva aims to pare down costs, streamline the organization and boost business performance, profitability, cash flow generation and productivity, Schultz said. The company has had to downsize its guidance again and again thanks to generics pricing pressure and a pile of dealmaking debt.

“These are decisions I don’t take lightly but they are necessary to secure Teva’s future. We will implement these changes with fairness and the utmost respect for our colleagues worldwide,” he said.

The two-year plan aims to cut Teva’s costs by $3 billion by the end of 2019, from an estimated cost base of $16.1 billion for 2017. But the restructuring itself will end up costing the company at least $700 million in 2018, according to a statement. And the price tag could be even higher, depending on how many manufacturing plants, R&D sites and other office locations the company decides to shut or sell.

By Amirah Al Idrus

Source: Fierce Biotech

comments closed

Related News

September 25, 2022

Rise of the machines: Novo Nordisk pledges $200M to create first quantum computer for life sciences

Life sciences

Big Pharma has long seen the potential for AI and machine learning to accelerate drug development. But Novo Nordisk is going a step further by channeling $200 million toward the creation of a computer that will outrun anything in existence.

September 25, 2022

Mount Sinai AI uncovers new brain analysis method to predict dementia, Alzheimer’s disease

Life sciences

Current methods for diagnosing Alzheimer’s disease rely on a complex combination of self- and caregiver-reported symptoms, a physical examination and either a PET scan or a spinal tap to look for evidence of amyloid plaque build-ups in the brain. But a new artificial intelligence-based method may make the diagnostic process a much more objective one.

September 25, 2022

New AstraZeneca-backed report finds big money behind diverse owners and entrepreneurs in Europe

Life sciences

There is lots of talk about diversity and inclusion in business, including in pharma and medtech. A new report by the Open Political Economy Network (OPEN), a think tank focusing on migration and diversity, released its “Minority Businesses Matter: Europe” report highlighting the successes and challenges of ethnic minority-owned businesses in Europe.